24/7 Market News Snapshot 30 January, 2025 – Enveric Biosciences, Inc. Common Stock (NASDAQ:ENVB)

January 30, 2025

DENVER, Colo., 30 January, 2025 (247marketnews.com) – (NASDAQ:ENVB) are discussed in this article.
Enveric Biosciences, Inc. (NASDAQ:ENVB), a biotechnology company focusing on developing neuroplastogenic therapeutics for mental health disorders, has witnessed a dramatic rise in its stock price, opening at $4.28 and surging by nearly 25% to reach $5.37. This surge, accompanied by a trading volume of 1.00 million shares, reflects a robust investor interest and optimism surrounding the company’s strategic initiatives and development potential.

A major catalyst for this positive market response is the recent Notice of Allowance (NOA) granted by the United States Patent and Trademark Office (USPTO) for a critical patent application linked to Enveric’s EVM301 Series of molecules. This patent, titled “N-Hetercycle Substituted Tryptamine Derivatives and Methods of Using,” relates to a novel series of tryptamine derivatives aimed at treating severe mental health conditions such as depression, anxiety, and addiction. Specifically, the claims involved are centered on Enveric’s lead candidate, EB-003, which is preparing to enter preclinical development stages before undergoing an Investigational New Drug (IND) application.

Dr. Joseph Tucker, Director and CEO of Enveric, articulated that this NOA signifies a substantial advancement for the company and its mission to develop EB-003 as a transformative treatment for treatment-resistant disorders. He noted that EB-003 is designed to promote neuroplasticity without the visual disturbances seen in traditional psychedelic therapies, setting a potential new standard in mental health interventions that can be administered safely outside of medical settings.

Additionally, Enveric’s diverse portfolio, which includes 12 granted U.S. patents along with several international applications, further fortifies its position in the biotech landscape. As the company moves forward with clinical trials and continues to expand its intellectual property, stakeholders and the wider community remain highly attentive to developments that could reshape mental health treatment paradigms.

Related news for (ENVB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.